Tomorrow the Danish Genmab will publish its past quarters figures. For this year Genmab's revenue will be around 4,61 billion Danish Krone. This is according to the average of the analysts' estimates. This is rather significant more than 2018's revenue of 3,03 billion Danish Krone.
The analysts expect for 2019 a net profit of 1,77 billion Danish Krone. For this year most of the analysts expect a profit per share of 28,46 Danish Krone. Based on this the price/earnings-ratio is 44,82.
For this year most of the analysts expect a dividend of 0,22 cents per share. Thus the dividend yield equals 0,02 percent. The average dividend yield of the pharmaceutical companies equals a limited -3 percent.
Genmab's market capitalization is based on the number of outstanding shares around 77,91 billion Danish Krone. The Genmab stock was the past 12 months quite volatile. Since last August the stock is 18 percent higher. This year the stock price moved between 786 and 1308 DKK.
ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.